1. Glycogen synthase kinase-3 beta (GSK3β)-mediated phosphorylation of ETS1 promotes progression of ovarian carcinoma.
- Author
-
Tsai CL, Jung SM, Chi LM, Tsai CN, Lin CY, Chao A, and Lee YS
- Subjects
- Amino Acid Sequence, Animals, Cell Line, Tumor, Cell Movement genetics, Female, Humans, Matrix Metalloproteinase 9 metabolism, Mice, Inbred C57BL, Models, Biological, Mutation genetics, Neoplasm Staging, Phosphorylation, Protein Binding, Protein Stability, Proto-Oncogene Protein c-ets-1 chemistry, Proto-Oncogene Protein c-ets-1 genetics, Serine metabolism, Substrate Specificity, Threonine metabolism, Mice, Disease Progression, Glycogen Synthase Kinase 3 beta metabolism, Ovarian Neoplasms metabolism, Ovarian Neoplasms pathology, Proto-Oncogene Protein c-ets-1 metabolism
- Abstract
ETS1 - an evolutionarily conserved transcription factor involved in the regulation of a number of cellular processes - is overexpressed in several malignancies, including ovarian cancer. Most studies on ETS1 expression have been focused on the transcriptional and RNA levels, with post-translational control mechanisms remaining relatively unexplored in the pathogenesis of malignancies. Here, we show that ETS1 forms a complex with glycogen synthase kinase-3β (GSK3β). Specifically, GSK3β-mediated phosphorylation of ETS1 at threonine 265 and serine 269 promoted protein stability, induced the transcriptional activation of matrix metalloproteinase ( MMP ) -9 , and increased cell migration. In vivo experiments revealed that a GSK3β inhibitor was able to suppress both endogenous ETS1 expression and induction of MMP-9 expression. Upon generation of a specific antibody against phosphorylated ETS1, we demonstrated that phospho-ETS1 immunohistochemical expression in ovarian cancer specimens was correlated with that of MMP-9. Notably, the cumulative overall survival of patients with low phospho-ETS1 histoscores was significantly longer than that of those showing higher scores. We conclude that the GSK3β/ETS1/MMP-9 axis may regulate the biological aggressiveness of ovarian cancer and can serve as a prognostic factor in patients with this malignancy.
- Published
- 2021
- Full Text
- View/download PDF